• Ziprasidone Augmentation in Escitalopram-Treated Anxious Dep

  2026-06-19

  This article examines a randomized, controlled trial evaluating ziprasidone augmentation in patients with major depressive disorder (MDD) and co-occurring anxiety who are treated with escitalopram. The study found that adding ziprasidone did not significantly improve depressive or anxiety symptoms compared to placebo, emphasizing the complexity of treating anxious depression and the importance of nuanced research approaches.

• Urolithin A in Mitochondrial Biogenesis Research: Applied Wo

  2026-06-18

  Urolithin A (3,8-dihydroxy-6H-benzo[c]chromen-6-one) delivers unique experimental leverage as a mitophagy activator and anti-inflammatory compound, validated for mitochondrial biogenesis research. This article translates the latest mechanistic findings and protocol optimizations into actionable workflows, troubleshooting insights, and translational outlooks for aging, fibrosis, and metabolic disease models.

• Hypoxia-Activated Photomolecular Glues Enhance Tumor Selecti

  2026-06-18

  This study introduces a hypoxia-activated photomolecular glue (BNNC) that combines selective Cyclin K degradation with phototherapy, enhancing antitumor efficacy and minimizing off-target toxicity. The approach leverages tumor hypoxia to trigger the release of synergistic agents and demonstrates substantial tumor inhibition and biosafety in breast cancer models.

• IDH2 Drives TNBC Proliferation via Ferroptosis Suppression P

  2026-06-17

  This study identifies isocitrate dehydrogenase 2 (IDH2) as a key regulator of triple-negative breast cancer (TNBC) proliferation through inhibition of ferroptosis. Integrated transcriptomic, clinical, and experimental analyses demonstrate that IDH2 overexpression suppresses ferroptotic cell death, highlighting a novel mechanism underlying TNBC aggressiveness and a potential metabolic vulnerability.

• AR and ARv7 Drive Poor Prognosis in TNBC: Insights into Enza

  2026-06-17

  This study elucidates the prognostic significance of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), demonstrating that their expression is linked to metastasis and reduced survival. Targeting AR and ARv7 with Enzalutamide or EPI-001 in TNBC models modulates key regulators of metastasis and epithelial–mesenchymal transition, suggesting actionable pathways for translational research.

• Super-Enhancer RNA Drives NPC Metastasis via NPM1/c-Myc/NDRG

  2026-06-16

  This study uncovers how carcinogen-induced super-enhancer RNA (seRNA-NPCm) promotes nasopharyngeal carcinoma (NPC) metastasis by regulating NDRG1 transcription through the NPM1/c-Myc complex. The findings highlight an epigenetic mechanism linking environmental carcinogen exposure to metastatic progression, with implications for biomarker discovery and targeted research.

• Latrunculin A: Applied Use in Actin Assembly and Cytoskeleto

  2026-06-16

  Latrunculin A, a reversible inhibitor of actin assembly from APExBIO, empowers researchers to dissect cytoskeletal dynamics in cell migration, tumor biology, and regenerative neuroscience. This guide details practical workflows, optimization strategies, and troubleshooting insights for leveraging Latrunculin A in both classic and emerging experimental contexts.

• MDM1 Overexpression Enhances Chemoradiotherapy Sensitivity i

  2026-06-15

  This study reveals that MDM1 overexpression increases p53 levels and apoptosis, thereby sensitizing colorectal cancer cells to chemoradiotherapy. The findings suggest MDM1 as a promising biomarker for predicting treatment response and guiding individualized therapy strategies.

• ZCL278: Selective Cdc42 Inhibitor for Cell Motility Research

  2026-06-15

  ZCL278 stands out as a selective Cdc42 inhibitor, enabling precise dissection of cell motility and neuronal branching pathways. Its robust performance in cancer, fibrosis, and neurodevelopmental models empowers researchers to unlock nuanced insights where older tools fall short.

• Small-Molecule Inhibition of uPAR–uPA Blocks Breast Cancer M

  2026-06-14

  This study introduces IPR-803 as a potent small-molecule inhibitor targeting the uPAR–uPA interaction, a central driver of tumor invasion and metastasis. Using biochemical, cellular, and in vivo models, the research demonstrates the compound's efficacy in reducing breast cancer metastasis and highlights its translational potential as a template for next-generation urokinase receptor inhibitors.

• Dextran Sulfate Sodium Salt in Mouse Colitis Models: Protoco

  2026-06-13

  Dextran sulfate sodium salt (MW 35000-45000) from APExBIO stands as the gold-standard chemical inducer for reliable mouse models of inflammatory bowel disease, uniquely enabling investigations into epithelial barrier dysfunction and mucosal repair. This article delivers evidence-informed protocols, troubleshooting strategies, and actionable guidance rooted in the latest mechanistic research for maximizing DSS-based workflows.

• Enhancing Kidney-Targeted mRNA Nanoparticles: Excipients and

  2026-06-12

  This study explores how various excipients improve the mRNA loading efficiency of polymeric mesoscale nanoparticles for kidney-targeted delivery. The findings provide actionable insights for optimizing mRNA nanoparticle formulations, with implications for both therapeutic and reporter gene mRNA applications.

• Airway Secretome Alterations in ALI Model Exposed to Ozone a

  2026-06-12

  This study applies an air–liquid interface (ALI) model of polarized airway epithelial cells to dissect how ozone (O3) and diesel exhaust particles (DEP) disrupt barrier integrity and modify the secretome. By highlighting convergent activation of Wnt signaling and antigen presentation pathways, the findings provide mechanistic insight into shared responses to mixed air pollutant exposure, informing future therapeutic strategies.

• Alda 1: Unveiling ALDH2 Activation for Cardiac Regeneration

  2026-06-11

  Explore how Alda 1, a potent ALDH2 activator, catalyzes breakthroughs in cardioprotection and cardiac regeneration research. This article provides new mechanistic insights and practical guidance for leveraging Alda 1 in advanced experimental workflows.

• QX77: Molecular Chaperone Activator for Autophagy Modulation

  2026-06-11

  QX77 empowers researchers to precisely upregulate LAMP2A and Rab11, enabling robust and reproducible chaperone-mediated autophagy studies. Its unique dual role as an autophagy activator and stem cell differentiation modulator opens new avenues for dissecting cellular pathways and troubleshooting autophagic flux in advanced workflows.

450 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page